TriangleNCT01696084 · OUTCOME
Overall Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- From the date of randomization to death from any cause
What was measured
Overall survival was measured from the date of randomization to death from any cause, subjects not known to have died by the last follow-up were censored on the date they were last known to be alive.
Analysis population: Intent-to-Treat (ITT) Population: All participants randomized in the study.
Groups in this outcome
Arm A (CPX-351)
Subjects are eligible to receive up to 2 inductions and up to 2 consolidations with CPX-351. The number of inductions and consolidations a subject received depended on response.
Arm B (7+3)
Subjects are eligible to receive up to 2 inductions and up to 2 consolidations with cytarabine and daunorubicin given as a 7 + 3, or 5 days of continuous infusion of cytarabine and 2 days of daunorubicin (5+2, second induction, consolidation courses) therapy. The number of inductions and consolidations a subject received depended on response.
| Group | Source count |
|---|---|
| Arm A (CPX-351) | 153 |
| Arm B (7+3) | 156 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Arm A (CPX-351) | 9.56 | Not reported | 6.60 | 11.86 | Not reported |
| Arm B (7+3) | 5.95 | Not reported | 4.99 | 7.75 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 6.60
- upper Limit
- 11.86
- value
- 9.56
- group Id
- OG001
- lower Limit
- 4.99
- upper Limit
- 7.75
- value
- 5.95
- denoms
- counts
- group Id
- OG000
- value
- 153
- group Id
- OG001
- value
- 156
- units
- Participants
- description
- Overall survival was measured from the date of randomization to death from any cause, subjects not known to have died by the last follow-up were censored on the date they were last known to be alive.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Subjects are eligible to receive up to 2 inductions and up to 2 consolidations with CPX-351. The number of inductions and consolidations a subject received depended on response.
- id
- OG000
- title
- Arm A (CPX-351)
- description
- Subjects are eligible to receive up to 2 inductions and up to 2 consolidations with cytarabine and daunorubicin given as a 7 + 3, or 5 days of continuous infusion of cytarabine and 2 days of daunorubicin (5+2, second induction, consolidation courses) therapy. The number of inductions and consolidations a subject received depended on response.
- id
- OG001
- title
- Arm B (7+3)
- param Type
- MEDIAN
- population Description
- Intent-to-Treat (ITT) Population: All participants randomized in the study.
- reporting Status
- POSTED
- time Frame
- From the date of randomization to death from any cause
- title
- Overall Survival
- type
- PRIMARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice